Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.50 |
| ▸ | HTR1A | P08908 | 2/20 | 0.50 |
| ▸ | CYP24A1 | Q07973 | 6/20 | 0.47 |
| ▸ | CYP27A1 | Q02318 | 3/20 | 0.47 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | HTR2B | P41595 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8190999 | 0.90 | HTR7 (0.52) | SIGMAR1CYP24A1CYP27A1CYP26A1DRD2 | |
| SCHEMBL6502043 | 0.89 | CYP24A1 (0.60) | SIGMAR1HTR1ACYP24A1CYP27A1CYP26A1 | |
| SCHEMBL6491492 | 0.87 | ADRA1D (0.54) | SIGMAR1HTR1ACYP24A1CYP27A1CYP26A1 | |
| SCHEMBL6503237 | 0.85 | SIGMAR1 (0.51) | SIGMAR1HTR1ACYP24A1DRD2HTR2A | |
| SCHEMBL6501747 | 0.84 | SIGMAR1 (0.53) | SIGMAR1HTR1ACYP26A1DRD2HTR2A | |
| SCHEMBL6492064 | 0.83 | SIGMAR1 (0.70) | SIGMAR1HTR1ADRD2HTR2AHTR2C | |
| SCHEMBL6502513 | 0.82 | SIGMAR1 (0.54) | SIGMAR1HTR1ACYP24A1CYP27A1CYP26A1 | |
| SCHEMBL6500048 | 0.80 | METAP1 (0.53) | SIGMAR1CYP24A1CYP27A1CYP26A1DRD2 | |
| SCHEMBL8199521 | 0.79 | DRD2 (0.58) | SIGMAR1CYP24A1CYP27A1CYP26A1DRD2 | |
| SCHEMBL8200794 | 0.78 | CYP24A1 (0.57) | SIGMAR1CYP24A1CYP27A1CYP26A1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1998036749-A1 | TETRALONE DERIVATIVES AS ANTIARRHYTHMIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-08-27 | — | — | WO | claimed |
| US-6969724-B2 | Compounds | SMITHKLINE BEECHAM-SPA (GB) | 2005-11-29 | — | — | US | disclosed |
| US-20040024218-A1 | Novel compounds | SMITHKLINE BEECHAM SPA | 2004-02-05 | — | — | US | disclosed |
| EP-1129072-A2 | N-SUBSTITUTED AZACYCLES, THEIR PREPARATION AND THEIR USE AS ORL-1 RECEPTOR LIGANDS | Smithkline Beecham S.p.A. (IT) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000027815-A2 | N-SUBSTITUTED AZACYCLES, THEIR PREPARATION AND THEIR USE AS ORL-1 RECEPTOR LIGANDS | SMITHKLINE BEECHAM SPA (IT) | 2000-05-18 | — | — | WO | disclosed |
| US-6048877-A | Tetralone derivatives as antiarrhythmic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024218-A1 | Novel compounds | OXER1, CLIC1, CCR1 | SIGMAR1 50/4885HTR1A 476/4885CYP24A1 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.